source
- Regeneron's Pasatru receives FDA approval for ultra-rare bone-growth disease FOPRegeneron Pharmaceuticals has secured FDA approval for Pasatru, a therapy aimed at treating fibrodysplasia ossificans progressiva (FOP), an ultra‑rare condition in which bone forms in soft tissues.…
- Experts split over Huidagene’s gene-editing approach after boy’s death in Duchenne trialA young boy died while participating in Huidagene’s gene‑editing trial for Duchenne muscular dystrophy, raising serious questions about the company’s experimental strategy. STAT+ reviewed video of…